Physician profile
Michael Donahue Decker
NPI 1710212840
$107,779.79
in general payments reported to CMS, 2019-2025
5 companies · $4,028 in 2025
The $4,028 reported for 2025 was more than what 89% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $41K · 2021: $14K · 2022: $9,692 · 2023: $2,806 · 2024: $6,686 · 2025: $4,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,519.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $83,644.71 | 2019-2024 | |
| Valneva USA, INC. | $7,579.83 | 2022-2025 | Ixchiq |
| Astrazeneca Pharmaceuticals Lp | $7,166.25 | 2024-2025 | Flumist Quadrivalent |
| Emergent Biosolutions INC. | $6,323.33 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $3,065.67 | 2022-2023 | Prehevbrio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Decker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.